This article is more than 5 years old. Information may no longer be current.
NICE gives qualified nod to Eylea for treatment of diabetic macular edema
Click Here to Manage Email Alerts
The National Institute for Health and Care Excellence has provisionally recommended Eylea as an option for treating diabetic macular edema in preliminary technology appraisal guidance, according to an agency release.
Aflibercept (Eylea, Bayer) is recommended when central retinal thickness is 400 µm or more at the start of treatment and when the manufacturer provides aflibercept at an agreed upon discount, according to the agency release.
In a Bayer press release, the company reacted by saying, “Bayer is disappointed that a core group of patients diagnosed with early stage [diabetic macular edema] (central retinal thickness < 400 µm) would be denied treatment until their disease has progressed to a stage where permanent damage to the eye has already begun.”
A final decision is expected in June.